ERAP1 and cancer: Since ERAP1 is a target molecule for cancer immunotherapy, it may be worth exploring whether its secondary effects on the proteome and metabolism of cancer may be exploited pharmacologically to synergize with the effects on adaptive immunity to enhance antitumor therapies.